Human Gene Therapy Subcommittee - 7/30/90 
6. Do TNF^TIL respond to steroids? 
Dr. Mclvor asked if Dr. Rosenberg knew whether responds to 
steroids in vitro. Dr. Rosenberg said he didn't know, but that 
an IL-2 dependent cell in the presence of IL-2 will not be 
affected by steroids in vitro. However, in the absence of IL-2 
and in human studies in which steroids were administered in the 
presence of LAK and IL-2, the steroids produced a marked 
reduction in IL-2 toxicity in the patients and allowed one to 
give IL-2 longer without seeing toxicity. 
7. What is the current situation with respect to the 
availability of anti-TNF antibody? 
Dr. Mclvor said this issue had been satisfactorily addressed. 
8. How were the TIL infections performed considering the 
low titer of the virus? 
Dr. Mclvor said this issue was addressed by Dr. Rosenberg's 
comments . 
9. How many dry runs have been performed and what is the 
Southern data on these? Is proviral structure and copy 
number maintained? Are these data availeUale to see? 
Dr. Mclvor said he would still like to see additional Southern 
data on material from other patients and other dry runs which Dr. 
Kasid has agreed to provide. 
10. What is the current status of marked TIL trafficking 
studies? Do they support homing at a level of .015% 
per gram? 
Dr. Mclvor asked if the N2/TIL protocol had provided any further 
insight into this question. Dr. Rosenberg said it had not, and 
they had not been able to get a good estimate of the incidence of 
marked cells at the tumor sites. He said it could be done in a 
single-cell suspension from peripheral blood but not from the 
tumor. He said he felt the indium^^^ studies were done quite 
carefully and are more reliable. 
11. In human experiments, how will one determine what part 
of the efficacy can be attributed to TMF gene transfer 
and expression? 
Dr. Mclvor called Dr. Rosenberg's attention to a sentence on page 
146 of the proposal that states that, "...detailed studies of 
[ 86 ] 
Recombinant DNA Research, Volume 14 
